TransMedics Group Inc

For the period ended Sep 30, 2024. Filed Oct 29, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Oct 29, 2024

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Accumulated
Other · Total
Common Stock · Comprehen- · Accumulated · Stockholders'
	Shares	Amount	sive Loss	Deficit	Equity
Balances at December 31, 2023	32,670,803	$641,106	$(199)	$(503,705)	$137,202
Issuance of common stock upon the exercise of common stock options	113,023	2,547	—	—	2,547
Issuance of common stock in connection with employee stock purchase plan	9,506	638	—	—	638
Vesting of restricted stock units	58,044	—	—	—	—
Stock-based compensation expense	—	6,870	—	—	6,870
Foreign currency translation adjustment	—	—	17	—	17
Net income	—	—	—	12,197	12,197
Balances at March 31, 2024	32,851,376	651,161	(182)	(491,508)	159,471
Issuance of common stock upon the exercise of common stock options	433,398	10,641	—	—	10,641
Vesting of restricted stock units	17,772	—	—	—	—
Issuance of common stock in connection with exercise of warrants	11,735	—	—	—	—
Stock-based compensation expense	—	7,643	—	—	7,643
Foreign currency translation adjustment	—	—	(55)	—	(55)
Net income	—	—	—	12,194	12,194
Balances at June 30, 2024	33,314,281	669,445	(237)	(479,314)	189,894
Issuance of common stock upon the exercise of common stock options	206,275	6,439	—	—	6,439
Issuance of common stock in connection with employee stock purchase plan	21,797	1,423	—	—	1,423
Issuance of restricted common stock	4,160	—	—	—	—
Vesting of restricted stock units	15,004	—	—	—	—
Stock-based compensation expense	—	7,944	—	—	7,944
Foreign currency translation adjustment	—	—	4	—	4
Net income	—	—	—	4,216	4,216
Balances at September 30, 2024	33,561,517	$685,251	$(233)	$(475,098)	$209,920

Accumulated
Other · Total
Common Stock · Comprehen- · Accumulated · Stockholders'
	Shares	Amount	sive Loss	Deficit	Equity
Balances at December 31, 2022	32,141,368	$666,277	$(225)	$(478,677)	$187,375
Issuance of common stock upon the exercise of common stock options	378,500	3,574	—	—	3,574
Issuance of common stock in connection with employee stock purchase plan	14,135	384	—	—	384
Stock-based compensation expense	—	3,921	—	—	3,921
Foreign currency translation adjustment	—	—	7	—	7
Net loss	—	—	—	(2,636)	(2,636)
Balances at March 31, 2023	32,534,003	674,156	(218)	(481,313)	192,625
Issuance of common stock upon the exercise of common stock options	39,158	705	—	—	705
Stock-based compensation expense	—	4,958	—	—	4,958
Purchase of capped calls related to convertible senior notes	—	(52,072)	—	—	(52,072)
Issuance of restricted common stock	9,772	—	—	—	—
Foreign currency translation adjustment	—	—	(2)	—	(2)
Net loss	—	—	—	(1,001)	(1,001)
Balances at June 30, 2023	32,582,933	627,747	(220)	(482,314)	145,213
Issuance of common stock upon the exercise of common stock options	47,438	952	—	—	952
Issuance of common stock in connection with employee stock purchase plan	11,759	571	—	—	571
Stock-based compensation expense	—	5,188	—	—	5,188
Foreign currency translation adjustment	—	—	(42)	—	(42)
Net loss	—	—	—	(25,422)	(25,422)
Balances at September 30, 2023	32,642,130	$634,458	$(262)	$(507,736)	$126,460

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.